EFFECTS OF ESLICARBAZEPINE ACETATE (BIA 2-093) ON COGNITIVE FUNCTION IN CHILDREN WITH PARTIAL ONSET SEIZURES: AN ADD-ON, DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTICENTRE CLINICAL TRIAL.

Trial Profile

EFFECTS OF ESLICARBAZEPINE ACETATE (BIA 2-093) ON COGNITIVE FUNCTION IN CHILDREN WITH PARTIAL ONSET SEIZURES: AN ADD-ON, DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTICENTRE CLINICAL TRIAL.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2017

At a glance

  • Drugs Eslicarbazepine acetate (Primary)
  • Indications Epilepsy; Partial epilepsies
  • Focus Therapeutic Use
  • Sponsors Bial
  • Most Recent Events

    • 23 Jun 2017 Results from this study published in an Eisai Media Release.
    • 23 Jun 2017 According to an Eisai media release, data from this study were presented at the 12th European Paediatric Neurology Society (EPNS) Congress.
    • 18 Dec 2016 According to a Bial media release, based on the data from this study, one phase III study (profile 700046396) and from population PK modelling and exposure-efficacy analyses, the European Commission has extended the marketing authorisation for eslicarbazepine acetate as a once-daily adjunctive treatment for patients aged above six years with partial-onset (focal) seizures with or without secondary generalisation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top